- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
New c-FIND test accurately diagnoses infection in minutes
1 July 2020
Institute researchers have developed a fast, new test for infections and infectious diseases that could transform Australia’s ability to provide targeted clinical care and respond to pandemics and biosecurity threats.
Called c-FIND, the test has the potential to rapidly and accurately detect multiple viral, bacterial or fungal infections within minutes – much faster than existing tests which can take days, or even weeks, to return a result.
and Associate Professor Marco Herold pictured
with a model of the c-FIND diagnostic device.
The test is now being developed into a portable, ‘point-of-care’ diagnostic device. Equipping clinicians with this device would enable them to diagnose infections without delay, and immediately provide the best care to high-risk patients, such as people with cancer.
The c-FIND program of research is being led by the Walter and Eliza Hall Institute of Medical Research, in collaboration with Melbourne Health, Murdoch Children’s Research Institute, Peter MacCallum Cancer Centre, The Royal Children’s Hospital, University of Melbourne, as well as industry partner and local biomedical technology company, Axxin Pty Ltd.
Transforming clinical care
Development is now underway to translate the c-FIND test into a portable, point-of-care device.
Following a successful bid for $1 million in funding from the Australian Government Medical Research Future Fund Frontiers program, the c-FIND research team is applying for funding that will include support for 13 clinical trials to rigorously assess implementation of the c-FIND diagnostic device in Australian healthcare settings with urgent, unmet diagnostic needs.
The trials aim to help advance Australia’s ability to rapidly and accurately diagnose:
- COVID-19 and other existing and emerging biosecurity threats
- high-risk cancer patients with asymptomatic or hard-to-detect infections
- infections in infants and children, and
- latent tuberculosis
Institute infectious disease physician and researcher Professor Marc Pellegrini said the c-FIND device could profoundly change how infections were detected and treated in a range of settings including hospitals, GP clinics, airports and ports of entry, and regional or remote centres.
“The introduction of a fast, reliable, user-friendly, point-of-care device to diagnose infections and infectious diseases on the spot, and even determine antimicrobial resistance, would be a game-changer for improving targeted patient care,” he said.
“c-FIND could prevent patients with hard-to-diagnose or hard-to-detect infections from waiting days, or weeks, for test results to come back whilst having expensive drug treatments, or unnecessary and invasive procedures.”
Pandemic preparedness
Professor Marc Pellegrini
Professor Pellegrini said the global COVID-19 pandemic had highlighted weaknesses in Australia’s ability to quickly detect, diagnose and respond to infectious disease threats.
“The current way that we test for COVID-19 is labour intensive, requiring highly trained staff, a central laboratory and expensive equipment to process samples. It can take days for patients to receive results, increasing the likelihood of disease transmission within the community,” Professor Pellegrini said.
“If a system such as c-FIND was available in the market, it could prevent disease spread and save lives by identifying infected people when they are tested so they can be isolated and treated without delay. It is widely accepted that pandemics will become more frequent in the future. A diagnostic device such as c-FIND would advance our capability to successfully respond to these emerging threats.”
Peter Mac infectious disease physician and associate director of health services research Professor Karin Thursky said the pandemic had knock-on effects for other parts of the healthcare system, such as cancer care, and significant impacts on vulnerable patients.
“With COVID-19 in the community, cancer patients are at significant risk and hospitals are having to put measures in place to protect them. This has meant that any cancer patient who presents with fever or respiratory symptoms is placed in strict isolation, and treated as COVID-19-positive until they return two negative results. These measures are distressing for patients and their loved ones, cause delays to cancer treatment being able to progress and place an additional burden on the healthcare system,” Professor Thursky said.
How does c-FIND work?
Institute CRISPR expert Associate Professor Marco Herold and his team have successfully adapted CRISPR for the development of the c-FIND test. The use of CRISPR technology in the diagnostics space has unleashed exciting potential to accurately detect genetic traces of disease-causing microbes within minutes.
“Once fully developed, the c-FIND diagnostic would involve taking a blood, mucus or saliva sample from a patient and – with minimal preparation – applying this to a small cartridge. This cartridge would then be run through the device to rapidly screen for as many as eight different viral, fungal or bacterial organisms at a time,” Associate Professor Herold said.
“c-FIND is fast as well as highly sensitive and specific. This means the technology has the ability to accurately identify if a person has certain infections, as well as rule out the infections a person does not have – it is unique for a test to excel in both these capabilities. Additionally, the system can be easily adapted to test for new and emerging infections,” he said.
Australian-led innovation
Institute director Professor Doug Hilton said c-FIND was a terrific example of Australian-led innovation and collaboration.
“c-FIND is the result of key collaborations between medical researchers, clinicians, hospitals and industry, leveraging their networks to produce a commercially-viable and competitive product that could deliver significant health and economic benefits to Australia and globally. It underscores Australian ingenuity and our self-sufficiency on the global stage,” Professor Hilton said.
“It is an incredibly exciting and potentially game-changing technology and I hope that further support can be secured so the team of talented researchers and clinicians can take this program of work to the next level and rigorously test the ability of c-FIND to improve Australian healthcare.”
About the Institute’s COVID-19 response
The Walter and Eliza Hall Institute is leading a number of major research responses to COVID-19 in collaboration with research partners in universities, hospitals and the private sector.
Our researchers are working towards better approaches to diagnose, treat and prevent the spread of coronaviruses, both to address the current COVID-19 global outbreak, as well as in preparedness for future coronaviral disease outbreaks.
Media inquiries
M: +61 475 751 811
E: communityrelations@wehi.edu.au
Super Content:
Answers to common questions about the c-FIND diagnostic device for testing infections and infectious diseases.
Our researchers are working towards better approaches to diagnose, treat and prevent the spread of coronaviruses, both to address the current COVID-19 global outbreak as well as in preparedness for likely future coronaviral disease outbreaks.
Australia's first clinical trial to determine whether hydoroxychloroquine can prevent COVID-19 is open. The trial is recruiting frontline and allied healthcare workers from hospitals across the country.
The Australian Government will invest $3M in Walter and Eliza Hall Institute research programs that are developing new classes of medicines for COVID-19.
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.